Open AccessA multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
Author(s) -
Christos Fountzilas,
Madhulika A. Gupta,
Sun Young Lee,
Smitha Krishnamurthi,
Bassam Estfan,
Katy Wang,
Kristopher Attwood,
John H. Wilton,
Robert Bies,
Wiam Bshara,
Renuka Iyer
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0737-6
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , dosing , oncology , pharmacokinetics , cancer , pharmacodynamics , durvalumab , urology , tolerability , surrogate endpoint , adverse effect , nivolumab , immunotherapy
Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is an oral inhibitor of VEGFR-1/2/3 with promising activity against HCC in vivo.